McKesson Corp (MCK) stock
MCKNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3026% above fair value
$1102.81+25.76 (+2.39%)
Close on Nov 13, 2026Market cap $128.58BP/E 28.4Yield 0.29%
McKesson EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
McKesson's EPS for the twelve months ending Sep 30, 2026 was $38.87, up 21.0% year over year. For fiscal 2026 it was $38.38, up 49.2% from the year before. Over ten years it grew 14.7% a year on average. The highest annual figure on record is $38.38 in fiscal 2026.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $38.38 | +49.2% |
| FY2025 | Mar 31, 2025 | $25.72 | +14.9% |
| FY2024 | Mar 31, 2024 | $22.39 | -10.5% |
| FY2023 | Mar 31, 2023 | $25.03 | +246.2% |
| FY2022 | Mar 31, 2022 | $7.23 | – |
| FY2021 | Mar 31, 2021 | -$28.26 | -670.9% |
| FY2020 | Mar 31, 2020 | $4.95 | +2811.8% |
| FY2019 | Mar 31, 2019 | $0.17 | -46.9% |
| FY2018 | Mar 31, 2018 | $0.32 | -98.6% |
| FY2017 | Mar 31, 2017 | $22.73 | +134.3% |
| FY2016 | Mar 31, 2016 | $9.70 | +54.7% |
| FY2015 | Mar 31, 2015 | $6.27 | +15.9% |
| FY2014 | Mar 31, 2014 | $5.41 | -3.2% |
| FY2013 | Mar 31, 2013 | $5.59 | 0.0% |
| FY2012 | Mar 31, 2012 | $5.59 | +22.3% |
| FY2011 | Mar 31, 2011 | $4.57 | -1.1% |
| FY2010 | Mar 31, 2010 | $4.62 | +56.6% |
| FY2009 | Mar 31, 2009 | $2.95 | -11.1% |
| FY2008 | Mar 31, 2008 | $3.32 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $10.44 | +17.0% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $5.15 | -17.6% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $13.69 | +36.9% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $9.59 | +38.0% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $8.92 | +377.0% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $6.25 | -10.7% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $10.00 | +66.4% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $6.95 | +57.2% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $1.87 | -62.0% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $7.00 | -0.3% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $6.01 | +5.1% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $4.42 | -42.3% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $4.92 | -23.4% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $7.02 | +33.5% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $5.72 | +131.6% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $7.66 | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $6.42 | +275.4% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $5.26 | +71.3% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $2.47 | -40.5% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$0.04 | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $1.71 | -51.7% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $3.07 | +12.9% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $4.15 | -29.1% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$39.03 | -3889.3% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $3.54 | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $2.72 | +21.4% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $5.85 | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $1.03 | -57.1% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$3.99 | -259.0% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $2.24 | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$4.17 | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $2.40 | -44.6% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $2.51 | +25000.0% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$0.68 | -146.9% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$5.58 | -133.3% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $4.33 | +51.9% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $0.01 | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $1.45 | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $16.76 | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $2.85 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?